Clinical trial · Interventional
A Study of BGM-2121 in Patients With Advanced Solid Tumors
A Phase 1 First-in-human Study of BGM-2121 in Patients With Advanced Solid Tumors
NCT07346846CI-TRIAL-00108974recruitingPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is to explore the safety, tolerability, pharmacokinetics, and preliminary efficacy of BGM-2121 in adult patients with advanced solid tumors.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Solid Tumors | Solid Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| BGM-2121 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- BGM-2121
- interventionNames
- Drug: BGM-2121
Primary outcomes (5)
- measure
- Incidence of Dose-Limiting Toxicities (DLTs)
- timeFrame
- From first dose through the DLT evaluation period (28 days)
- description
- Number and type of DLTs observed following administration of BGM-2121 at different dose levels, assessed according to protocol-defined criteria.
- measure
- Treatment Discontinuation Due to Drug-Related Adverse Events
- timeFrame
- From first dose through study completion, an average of 1 year
- description
- Number of participants who permanently discontinue BGM-2121 due to drug-related adverse events, graded per CTCAE v5.0.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. With either gender aged ≥ 18 years, 2. Has a confirmed diagnosis of advanced solid tumor(s), 3. The subject has received and failed standard-of-care anti-cancer therapy 4. Has at least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) 5. ... Exclusion Criteria: 1. Has any ongoing toxicity from previous anti-cancer treatments 2. Has signs or symptoms of end-stage organ failure, major chronic illnesses other than cancer(s) 3. History of another primary malignancy within the last three years 4. ...
References
Publications (0)
Data not yet available
No reference posted for this study.